vVARDIS Holding AG Form 424B4 — Nov 16, 2026
vVARDIS Holding AG priced its IPO at $18.00 per Class A ordinary share, offering 9,722,223 shares for approximately $175.0 million in gross proceeds ($154.5 million net), with a 1,458,333-share over-allotment option. The shares will list on the NYSE under the symbol VVVV, led by Goldman Sachs and J.P. Morgan, with a 180-day lockup (270 days for the Co-Founders). The company is a Swiss oral-health company commercializing Curodont, a peptide-based drill-free treatment for early-stage cavities distributed exclusively in the U.S.
Key figures
- Revenue
- 30209000
- Guidance
- Preliminary nine months ended September 30, 2026: net revenue $47.7M-$49.2M, gross profit $41.1M-$42.3M (86.0%-86.2% margin), net loss $(39.7)M-$(41.3)M, Adjusted EBITDA $(9.2)M-$(9.4)M
- Revenue Yoy
- 148.5% for FY2025; 214.2% for the six months ended June 30, 2026; 114.0%-120.8% expected for the nine months ended September 30, 2026
- Total Assets
- 104803000
- Cash Position
- $28,974 thousand as of June 30, 2026; estimated $19.4 million as of September 30, 2026
- Gross Proceeds
- 175000014
- Offering Price
- 18
- Shares Offered
- 9722223
- Total Debt
- Total liabilities of $164.4 million as of June 30, 2026
- Net Proceeds
- $154.5 million (approximately $178.9 million with over-allotment in full)
- Greenshoe Shares
- 1458333
- Fy2025 Gross Margin
- 74.2%
- Accumulated Deficit
- $256.3 million as of June 30, 2026
- Founder Voting Power
- 86.9%
- H1 2026 Gross Margin
- 86.4%
- Recurring Buying Practices
- 11,158 as of Q3 2026
- Underwriting Discount Per Share
- 1.26
AI analysis
Red flags7 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.